A. | ||||||
CVD risk predicted by age + sex model | CVD risk predicted by MBDA-based CVD model | Observed cumulative incidence | Total patients (n) within category of age + sex model and % reclassified | |||
Low (< 1.3%) | Borderline (1.3 to < 1.8%) | Intermediate (1.8 to < 5.2%) | High (≥ 5.2%) | |||
Low (< 1.3%) | 2.6% | 0.9% | 0.9% | < 0.1% | 1.4% | 460 (42.6%) |
Borderline (1.3 to < 1.8%) | 1.7% | 1.4% | 2.5% | 0.2% | 1.3% | 600 (75.3%) |
Intermediate (1.8 to < 5.2%) | 4.9% | 7.3% | 37.1% | 11.0% | 3.7% | 6185 (38.4%) |
High (≥ 5.2%) | 0.1% | 0.6% | 11.8% | 17.0% | 7.8% | 3030 (42.4%) |
Observed cumulative incidence | 0.9% | 1.7% | 3.1% | 9.9% | – | – |
B. | ||||||
CVD risk predicted by clinical + CRP model | CVD risk predicted by MBDA-based CVD model | Observed cumulative incidence | Total patients (n) within category of clinical + CRP model and % reclassified | |||
Low (< 1.3%) | Borderline (1.3 to < 1.8%) | Intermediate (1.8 to 5.2%) | High (≥ 5.2%) | |||
Low (< 1.3%) | 4.4% | 1.2% | 0.5% | 0.0% | 1.3% | 627 (28.2%) |
Borderline (1.3 to < 1.8%) | 3.0% | 3.0% | 2.3% | < 0.1% | 1.3% | 853 (64.4%) |
Intermediate (1.8 to < 5.2%) | 2.0% | 6.0% | 41.5% | 5.4% | 3.1% | 5644 (24.4%) |
High (≥ 5.2%) | 0 | < 0.1% | 7.9% | 22.7% | 9.3% | 3151 (26.0%) |
Observed cumulative incidence | 0.9% | 1.7% | 3.1% | 9.9% | – | – |